All In Biotech

Drug Trial Radar · NCT04999488

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older

Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Dec 2023

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
AdventHealth Translational Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being done to gather data on whether oral supplementation of CoQ10 is enriched in the blood and muscles in older adults with sarcopenia. This study involves 28 consecutive days of oral CoQ10 supplementation to explore changes in muscle strength, aerobic capacity and physical function with CoQ10 supplementation.

Conditions

  • Sarcopenia

Interventions

  • BPM31510Drug

    A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.

  • PlaceboOther

    A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of skeletal muscleTime frame: Following 28 days of treatment
  2. Measurement of platelet CoQ10 levelTime frame: Following 28 days of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • AdventHealth Translational Research Institute

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.